![]() ![]() All stock and related investments have a degree of risk, which can result in a significant or total loss. Past performance is not indicative of future results, which may vary. No representation is being made that an account will or is likely to achieve profit or losses similar to those shown. ![]() The performance results obtained are intended for illustrative purposes only. Hypothetical or simulated performance results have limitations, and unlike an actual performance record, simulated results do not represent actual trading and consequently do not involve financial risk of actual trading. Historical performance figures provided are hypothetical and unaudited, and based on our proprietary analysis and system performance, back-tested over a period of time. We are not a Registered Investment Advisor (RIA). Graycell Advisors, and its affiliates, officers, employees, families, and all other related parties, collectively referred to as ‘Graycell’ and/or ‘we,’ is a publisher of financial information, such as the Smallcap, and Prudent Biotech newsletters. The ability to exit the market is relatively easier for individual investors, compared to institutional investors, and we should leverage that into an advantage during times of acute market stress or a downward trend. Consequently, the Prudent Biotech portfolio simply exited to the safety of cash. The models recognized the market risk to be abnormally elevated and found a scarcity of investing ideas with a higher probability of success. What is equally noteworthy is the consistency with which the Prudent Biotech portfolio has outperformed each year in the last decade.ĭuring the brutal bear market of 2008-09, when the S&P 500 plunged 55% in a matter of months, the model portfolio did not suffer a material decline. The numbers get quite staggering if one calculates the model portfolio performance from 2003. Nonetheless, the performance gap is substantial, compelling & transformational.Ī $10,000 investment in 2010 in the biotech index would have also grown, Furthermore, historical results do not guarantee future performance. Generally speaking, biotech stocks have more variable returns and higher risk than the broader market indexes. ![]() Now keep in mind that the newsletter was available for subscription from mid-2015, and the prior performance is a back-tested track record based on hypothetical trades. ![]()
0 Comments
Leave a Reply. |